AHA 22: PRECISION: Aprocitentan in the Treatment of Resistant Hypertension | Dr Markus P Schlaich

Visit Radcliffe Cardiology: www.radcliffecardiology.com/?...
Dr Markus P Schlaich (University of Western Australia, AU) joins us to discuss the key findings from the PRECISION trial. This randomized, phase 3 study assessed the sustained blood pressure lowering effect of a dual endothelin receptor antagonist, aprocitentan in resistant hypertension.
Questions:
1. What are the unmet needs in patients with RHT? What is the rationale for PRECISION?
2. What is the study design, outcome measures and eligibility criteria?
3. What are the key results?
4. What are the take home messages for practice and research?
5. What are the next steps?
Recorded remotely from Perth, AHA 2022.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.